// App-Quantinova.ai

5006 : Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Researchers

Presenter

  • Susan Halabi

Principal Investigators

  • Larysa Rydzewska

  • Peter Godolphin

  • Mahesh K. B. Parmar

  • Maha H. A. Hussain

  • Catherine Tangen

  • Ian Thompson

  • Wanling Xie

  • Michael Anthony Carducci

  • Matthew Raymond Smith

  • Michael J. Morris

  • Gwenaelle Gravis

  • David P. Dearnaley

  • Paul Verhagen

  • Takayuki Goto

  • Nicholas D. James

  • Marc E. Buyse

  • Jayne F. Tierney

  • Christopher Sweeney

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Duke University, Durham, NC

  • Kings College London, London, United Kingdom

  • MRC Clinical Trials Unit, UCL, London, United Kingdom

  • Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Christus Health, San Antonio, TX.

  • Dana-Farber Cancer Institute, Boston, MA

  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine,, Baltimore, MD

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

  • Biostatistic, Institut Paoli-Calmettes, Aix-Marseille Universite, Marseille, France

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Erasmus University Medical Center, Rotterdam, Netherlands

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • Institute of Cancer Research, Birmingham, United Kingdom

  • International Drug Development Institute, Louvain-La-Neuve, Belgium

  • Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • United Kingdom

  • France

  • Netherlands

  • Japan

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved